All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The FDA grants GMI-1271 Breakthrough Therapy Designation for the treatment of R/R AML
Bookmark this article
On 17th March 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to GMI-1271, a novel E-selectin (E-sel) antagonist , for the treatment of patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1
E-sel is a cell adhesion molecule expressed constitutively in the bone marrow endothelium and it is involved in cell signaling and chemotaxis. Binding of AML blasts to E-selectin (E-sel), can lead to activation of leukemic cell survival pathways, thereby contributing to chemotherapy resistance. GMI-1271 is a novel antagonist of E-sel, which acts by disrupting leukemia cell survival pathways thus enhancing chemotherapy response.2,3
Currently, GMI-1271 is being explored in the phase 2 portion of the phase 1/2 study (NCT02306291), which is aiming to assess the safety, efficacy and pharmacokinetics of this agent in combination with standard chemotherapy in patients with R/R AML and also in AML patients 60 years of age and older with newly diagnosed disease.
- GlycoMimetics: GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia. 2017 May 17.http://ir.glycomimetics.com/releasedetail.cfm?ReleaseID=1026865 [Accessed 2017 May 18].
- National Cancer Institute: E-selectin antagonist GMI-1271. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=767121. [Accessed 2017 May 18].
- DeAngelo D. J. et al. A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. 2016 Dec 5. Abstract 2029. 58th Annual Meeting of the American Society of Hematology, San Diego, Ca.
More about...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox